Sandoz Gets New Leader: Is Restructuring Next For Novartis’ Generics Unit?
This article was originally published in The Pink Sheet Daily
Executive Summary
Andreas Rummelt will take over as head of the Sandoz generics business effective Nov. 1. His appointment reflects an enhanced focus on manufacturing and development rather than acquisitions, CFO Breu says. Novartis is re-evaluating the structure of Sandoz in light of difficult pricing environments in the U.S. and Germany.
You may also be interested in...
Generic Drug Price War Could Pay Off For PBMs
Pharmacy benefit managers earn higher profits on generics over brand products, Express Scripts CEO Toan says, and lower prices will lead to increased generic utilization. Caremark has gotten “some pickup” from the pricing competition, CEO Crawford says.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.